Novartis (NVS) to Release Quarterly Earnings on Tuesday

Novartis (NYSE:NVS) is expected to announce its earnings results before the market opens on Tuesday, April 22nd. Analysts expect the company to announce earnings of $2.07 per share and revenue of $12.92 billion for the quarter.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Stock Performance

NVS stock opened at $109.43 on Tuesday. The company has a market capitalization of $223.67 billion, a price-to-earnings ratio of 18.61, a P/E/G ratio of 1.70 and a beta of 0.56. The firm has a 50 day moving average of $108.95 and a two-hundred day moving average of $106.33. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. Novartis has a 12 month low of $92.35 and a 12 month high of $120.92.

Novartis Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s dividend payout ratio is presently 42.69%.

Hedge Funds Weigh In On Novartis

An institutional investor recently raised its position in Novartis stock. Brighton Jones LLC lifted its holdings in Novartis AG (NYSE:NVS) by 76.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,153 shares of the company’s stock after acquiring an additional 2,666 shares during the quarter. Brighton Jones LLC’s holdings in Novartis were worth $599,000 at the end of the most recent reporting period. 13.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Morgan Stanley began coverage on Novartis in a research report on Wednesday, February 12th. They issued an “underweight” rating for the company. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. UBS Group reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Finally, Barclays reissued an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Novartis currently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.